Webb & Tyler LLP
Size of Organization: 217
Year Established: 1919Web Site: http://www.pbwt.com
|Profile Visibility |
#877 in weekly profile views out of 279,958 total law firms Overall
Founded in 1919, Patterson Belknap is a law firm of over 200 lawyers delivering a full range of services across more than 20 practice groups in both litigation and commercial law. Our practice groups and attorneys are regularly ranked among the leaders in New York and nationally by the most respected industry guides, based on client and peer reviews. Clients include a diverse group of institutions and individuals: from pharmaceutical and medical device companies to major media and publishing empires; from consumer products companies to financial institutions; from fine art museums to famous entertainers; from foreign companies seeking to transact business on U.S. stock exchanges to U.S. companies doing business abroad. For more information about Patterson Belknap Webb & Tyler, please visit www.pbwt.com.
Martindale-Hubbell has augmented a firm's provided information with third-party sourced data to present a more comprehensive overview of the firm's expertise:
U.S. Federal Litigation Activity
Highest number of cases by Patterson Belknap
Webb & Tyler LLP:
Intellectual Property (47 cases in past two years)
Peer Review Ratings
Total number of Peer Review Rated lawyers of Patterson Belknap
Webb & Tyler LLP:
Documents by Patterson Belknap
Webb & Tyler LLP on Martindale.com
Appeals Court Confirms that Results of Internal Investigation are Privileged
Joshua A. Goldberg,Erik Haas,Deirdre A. McEvoy,Daniel S. Ruzumna,Harry Sandick, July 17, 2014
On June 27, 2014, the United States Court of Appeals for the District of Columbia Circuit issued a decision in In re: Kellogg Brown & Root, Inc., an important ruling which confirms the application of the attorney-client privilege to corporations within the business setting as set forth by the...
FDA Promises Guidance on Lawful Off-Label Promotion
Michael F. Buchanan,William F. Cavanaugh,Joshua A. Goldberg,Erik Haas,Daniel S. Ruzumna, July 17, 2014
Earlier this month, the U.S. Food and Drug Administration (the “FDA”) announced that by the end of the year, the agency would issue a draft guidance document addressing the contours of lawful and unlawful off-label promotion. The healthcare industry has heralded this announcement as a...
Supreme Court Rejects “Presumption of Prudence” in ESOP Cases
David M. Glaser,Erik Haas,James V. Masella, III,Bernard F. O'Hare,Peter W. Tomlinson, July 17, 2014
On June 25, 2014, the Supreme Court issued a decision in Fifth Third Bancorp v. Dudenhoeffer regarding the availability of relief against fiduciaries of an employee stock ownership plan (“ESOP”) for alleged breaches of the fiduciary duty of prudence in investing in employer stock.